United Therapeutics (NASDAQ:UTHR) Upgraded to Strong-Buy by StockNews.com

StockNews.com upgraded shares of United Therapeutics (NASDAQ:UTHRFree Report) from a buy rating to a strong-buy rating in a report published on Thursday.

A number of other brokerages have also recently issued reports on UTHR. SVB Leerink started coverage on shares of United Therapeutics in a report on Monday, February 5th. They issued an outperform rating and a $330.00 target price on the stock. Wells Fargo & Company raised their target price on shares of United Therapeutics from $309.00 to $325.00 and gave the stock an overweight rating in a report on Thursday, March 7th. The Goldman Sachs Group raised shares of United Therapeutics from a sell rating to a neutral rating and raised their target price for the stock from $213.00 to $215.00 in a report on Monday, February 12th. Wedbush reissued an outperform rating and issued a $308.00 target price on shares of United Therapeutics in a report on Thursday, February 22nd. Finally, HC Wainwright reissued a buy rating and issued a $300.00 target price on shares of United Therapeutics in a report on Thursday, February 22nd. One analyst has rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of Buy and a consensus target price of $294.40.

View Our Latest Stock Analysis on United Therapeutics

United Therapeutics Stock Down 1.0 %

Shares of United Therapeutics stock opened at $235.78 on Thursday. The business has a 50-day moving average of $222.68 and a 200-day moving average of $226.59. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.41 and a quick ratio of 4.28. The company has a market capitalization of $11.10 billion, a PE ratio of 11.88 and a beta of 0.52. United Therapeutics has a 1-year low of $204.44 and a 1-year high of $261.54.

United Therapeutics (NASDAQ:UTHRGet Free Report) last posted its quarterly earnings results on Wednesday, February 21st. The biotechnology company reported $4.36 EPS for the quarter, topping analysts’ consensus estimates of $4.28 by $0.08. The business had revenue of $614.70 million during the quarter, compared to the consensus estimate of $575.01 million. United Therapeutics had a return on equity of 17.72% and a net margin of 42.31%. The company’s revenue for the quarter was up 25.1% compared to the same quarter last year. During the same period last year, the firm earned $2.67 earnings per share. As a group, equities analysts forecast that United Therapeutics will post 23.15 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Nilda Mesa sold 605 shares of the stock in a transaction dated Tuesday, December 19th. The stock was sold at an average price of $244.90, for a total value of $148,164.50. Following the completion of the sale, the director now directly owns 5,698 shares of the company’s stock, valued at approximately $1,395,440.20. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other United Therapeutics news, Director Nilda Mesa sold 605 shares of the company’s stock in a transaction dated Tuesday, December 19th. The stock was sold at an average price of $244.90, for a total value of $148,164.50. Following the transaction, the director now directly owns 5,698 shares of the company’s stock, valued at approximately $1,395,440.20. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, EVP Paul A. Mahon sold 6,000 shares of the company’s stock in a transaction dated Thursday, December 21st. The stock was sold at an average price of $229.27, for a total value of $1,375,620.00. Following the completion of the transaction, the executive vice president now directly owns 36,599 shares in the company, valued at $8,391,052.73. The disclosure for this sale can be found here. In the last ninety days, insiders sold 32,285 shares of company stock valued at $7,162,165. Corporate insiders own 12.50% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Wellington Management Group LLP grew its holdings in United Therapeutics by 73.7% in the 1st quarter. Wellington Management Group LLP now owns 1,675,414 shares of the biotechnology company’s stock valued at $300,585,000 after buying an additional 710,668 shares during the last quarter. Norges Bank acquired a new stake in United Therapeutics in the 4th quarter valued at approximately $100,519,000. BlackRock Inc. grew its holdings in United Therapeutics by 7.3% in the 2nd quarter. BlackRock Inc. now owns 5,096,685 shares of the biotechnology company’s stock valued at $1,125,093,000 after buying an additional 344,724 shares during the last quarter. State Street Corp grew its holdings in United Therapeutics by 15.9% in the 1st quarter. State Street Corp now owns 1,795,102 shares of the biotechnology company’s stock valued at $402,031,000 after buying an additional 245,747 shares during the last quarter. Finally, Avidity Partners Management LP acquired a new stake in United Therapeutics in the 4th quarter valued at approximately $52,158,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

United Therapeutics Company Profile

(Get Free Report)

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Further Reading

Analyst Recommendations for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.